logo-loader

ReNeuron signs exosome collaboration deal with US biopharma

Last updated: 04:15 04 Jan 2019 EST, First published: 02:25 04 Jan 2019 EST

exosome
There will be no cash payment for this initial feasibility stage of the deal

An unnamed US biopharmaceutical company is to run the rule over ReNeuron Group Plc’s (LON:RENE) exosome drug delivery platform.

Under the terms of the collaboration agreement, the biopharma will explore the use of exosomes as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.

ReNeuron will provide the exosomes as well as sequence-based know-how while its new partner will provide its expertise in the field of synthetic oligonucleotides to optimise their loading into exosomes. 

READ: ReNeuron primed for significant commercial progress

“Exosomes are biological nanoparticles ideally suited to the delivery of nucleic acid-based therapeutics due to their natural occurrence and abundance, their ability to protect their cargo from degradation and their potential for favourable bio-distribution,” said ReNeuron chief executive Olav Hellebø.

“We are delighted to be collaborating with a biopharmaceutical company that has considerable experience in the development of novel oligonucleotide-based therapeutics.”

During the initial feasibility stage there are no cash payments between the parties, but should it prove successful, it is anticipated that a product cross-licensing agreement will be signed by the parties ahead of the pre-clinical and clinical development of the therapeutic candidates.

In early morning trading, ReNeuron shares were 6.2% higher at 51.50p.

 -- Adds share price --

ReNeuron has extended cash runway as it focuses on validating its exosome...

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors...

on 02/17/2023